Prevalence and risk factors for HBV and HCV among incarcerated people who inject drugs in Iran: a cross sectional study
Authors:
Preprint
- 21 February 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background This study aimed at determining the prevalence and risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV) among incarcerated people who inject drugs (PWID) in Iran during 2015-16. Methods The required data was obtained from the Iranian national bio-behavioral surveillance surveys (BBSSs), which examined 11988 prisoners who were selected using multi-stage sampling from 55 prisons in 19 provinces during 2015-16. The demographic and behavioral status of these subjects were measured through interviews and HBV and HCV exposure were examined using ELISA test of blood samples. A total of 1387 individuals with a history of drug injection in their lifetime were enrolled into this study. Survey analysis was used to analyze the data. The univariate and multivariate logistic regression were used to investigate the relationships between risk factors and outcome. Results The mean age of the incarcerated PWID was 36.83 ± 8.13; of all, 98.46% were male, 50.97% were married, and 96.57% had non-academic education. The prevalence of HCV and HBV was 40.52% and 2.46%, respectively. HCV prevalence was associated with an age≥30 years, being single, non-academic education, prison term>5 years, history of piercing, and extramarital sex in lifetime (P<0.05). Conclusions The prevalence of HCV is alarmingly high. However, prison by facilitating the easy access to infected group can be considered as an opportunity to achieve the goal of eliminating HCV in the country. It is recommended to design interventions while considering the risk factors of prison term, piercing, and extramarital sex.Keywords
All Related Versions
- Published version: BMC Infectious Diseases, 20 (1), 1.
This publication has 15 references indexed in Scilit:
- Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p studyInternational Journal of Drug Policy, 2018
- Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groupsBMC Infectious Diseases, 2018
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewThe Lancet Global Health, 2017
- Hepatitis C antibody prevalence among Mexico City prisoners injecting legal and illegal substancesDrug and Alcohol Dependence, 2017
- Modelling the impact of incarceration and prison‐based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in ScotlandAddiction, 2017
- Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detaineesThe Lancet, 2016
- The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013The Lancet, 2016
- Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugsBMC Public Health, 2014
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysisHepatology, 2013